TY - JOUR
TI - Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in
Malignant Pleural Mesothelioma A Single Institution Study
AU - Tourkantonis, Ioannis
AU - Makrilia, Nektaria
AU - Ralli, Maria and
AU - Alamara, Christina
AU - Nikolaidis, Ilias
AU - Tsimpoukis, Sotirios and
AU - Charpidou, Andriani
AU - Kotanidou, Anastasia
AU - Syrigos, Kostas
JO - AMERICAN JOURNAL OF CLINICAL ONCOLOGY - CANCER CLINICAL TRIALS
PY - 2011
VL - 34
TODO - 1
SP - 38-42
PB - Lippincott, Williams & Wilkins
SN - 0277-3732
TODO - 10.1097/COC.0b013e3181cae90e
TODO - docetaxel; gemcitabine; mesothelioma; second-line chemotherapy
TODO - Objective: The combinations of cisplatin-pemetrexed and
cisplatin-gemcitabine are considered the standard systemic therapy for
malignant pleural mesothelioma (MPM), which is a rapidly progressive
tumor. The purpose of the present study is to evaluate the efficacy,
safety, and clinical benefit of the gemcitabine plus docetaxel regimen
in the second-line treatment of this disease.
Patients and Methods: A total of 37 patients with MPM were treated with
the combination of docetaxel (80 mg/m(2)) and gemcitabine (1000 mg/m(2))
on day 1 and 14 of a 28-day cycle. The regimen was repeated for a
maximum of 6 cycles or until disease progression or unacceptable
toxicity.
Results: There was partial response of the disease in 7 patients
(18.9%), whereas it remained stable in 23 patients (62.2%) and
progressed in 7 patients (18.9%). The median time to disease
progression was 7 months (range: 5.8-8.2 months) with a mean survival of
16.2 months (range: 13-19.3 months).
Conclusion: The biweekly administration of docetaxel and gemcitabine,
along with granulocyte colony-stimulating factor support, constitutes a
safe, tolerable, and convenient regimen for the treatment of MPM,
suggesting that this combination may be a viable option, especially in
previously treated patients.
ER -